Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2021 07:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

New Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class

— New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors — Data differentiates ASLAN003 from first...
January 11, 2021 05:34 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial

- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
November 19, 2020 07:22 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference

SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
November 09, 2020 07:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

SINGAPORE, Nov. 09, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
October 22, 2020 07:30 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial

-- ASLAN has initiated recruitment of patients into third dose cohort at sites in the US, Australia and Singapore following successful safety review of second cohort -- ASLAN004 found to be...
October 16, 2020 05:25 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions

-- ASLAN believes ASLAN003 has the potential to be the most potent oral inhibitor of DHODH currently in development for autoimmune disease, more than 30 times more potent at inhibiting the DHODH...
September 21, 2020 06:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
September 10, 2020 03:08 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to...
August 24, 2020 03:27 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study

SINGAPORE, Aug. 24, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...
August 07, 2020 03:00 ET | Source: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020

SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative...

keyboard_arrow_left Previous Page